Everand Logo

Welcome to Everand!

  • STAT

    Pharma tries to cash in on migraine market by making new drugs free, for now

    With intense competition in the market for new migraine headache drugs, some companies are making their medicines free to patients with private insurance.
    by Damian Garde Sep 28, 2018 2 minutes

    With approval of a new migraine therapy, Eli Lilly has become the third drug company angling for dominance in what could become a multibillion-dollar market for preventing debilitating headaches. But because none of the three medicines is clearly better than another, the contenders are taking a novel approach to competition: giving drugs away for free.

    Lilly’s treatment, called Emgality, is an

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT1 min readIntelligence (AI) & Semantics
    STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
    CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Approval For Sarepta Drug, MSF Closing Access Campaign And More
    After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a controversial, long-running saga:
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About EMA Plans For GLP-1 Shortages, Walgreens Store Closings, And More
    The European Medicines Agency and member countries announced several steps to address shortages of GLP-1 drugs.

    Related